Bank of America
IBRX icon

Bank of America’s ImmunityBio IBRX Stock Holding History

Bank of America’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8M Buy
2,447,843
+65,340
+3% +$447K ﹤0.01% 2444
2025
Q4 		$4.72M Buy
2,382,503
+727,727
+44% +$1.65M ﹤0.01% 3446
2025
Q3 		$4.07M Sell
1,654,776
-7,101,407
-81% -$18.3M ﹤0.01% 4206
2025
Q2 		$23.1M Buy
8,756,183
+8,216,540
+1,523% +$22.1M ﹤0.01% 2412
2025
Q1 		$1.62M Buy
539,643
+278,910
+107% +$845K ﹤0.01% 4851
2024
Q4 		$667K Sell
260,733
-1,809,047
-87% -$7.54M ﹤0.01% 5329
2024
Q3 		$7.7M Buy
2,069,780
+1,111,253
+116% +$5.14M ﹤0.01% 3324
2024
Q2 		$6.06M Sell
958,527
-78,262
-8% -$516K ﹤0.01% 3442
2024
Q1 		$5.57M Buy
1,036,789
+144,974
+16% +$656K ﹤0.01% 3505
2023
Q4 		$4.48M Buy
891,815
+702,978
+372% +$2.21M ﹤0.01% 3641
2023
Q3 		$319K Buy
188,837
+95,770
+103% +$192K ﹤0.01% 5626
2023
Q2 		$259K Sell
93,067
-81,459
-47% -$230K ﹤0.01% 5659
2023
Q1 		$318K Sell
174,526
-588,268
-77% -$1.83M ﹤0.01% 5668
2022
Q4 		$3.87M Buy
762,794
+469,444
+160% +$2.58M ﹤0.01% 3636
2022
Q3 		$1.46M Buy
293,350
+245,781
+517% +$1.12M ﹤0.01% 4578
2022
Q2 		$177K Sell
47,569
-8,328
-15% -$33.5K ﹤0.01% 6176
2022
Q1 		$314K Sell
55,897
-106,291
-66% -$652K ﹤0.01% 6154
2021
Q4 		$987K Buy
162,188
+82,053
+102% +$616K ﹤0.01% 5280
2021
Q3 		$780K Buy
80,135
+23,845
+42% +$262K ﹤0.01% 5293
2021
Q2 		$804K Buy
56,290
+20,078
+55% +$332K ﹤0.01% 5068
2021
Q1 		$860K Buy
36,212
+17,190
+90% +$446K ﹤0.01% 4976
2020
Q4 		$254K Buy
19,022
+1,697
+10% +$16.3K ﹤0.01% 5448
2020
Q3 		$120K Buy
17,325
+430
+3% +$4.29K ﹤0.01% 5587
2020
Q2 		$207K Sell
16,895
-13,487
-44% -$76.2K ﹤0.01% 5223
2020
Q1 		$88K Buy
30,382
+28,253
+1,327% +$142K ﹤0.01% 5592
2019
Q4 		$8K Buy
2,129
+100
+5% +$170 ﹤0.01% 6686
2019
Q3 		$3K Sell
2,029
-20,627
-91% -$25.6K ﹤0.01% 6934
2019
Q2 		$24K Buy
22,656
+14,348
+173% +$16.6K ﹤0.01% 6525
2019
Q1 		$13K Sell
8,308
-21,897
-72% -$27.5K ﹤0.01% 6594
2018
Q4 		$34K Sell
30,205
-3,862
-11% -$8.84K ﹤0.01% 6339
2018
Q3 		$126K Buy
34,067
+19,323
+131% +$61.1K ﹤0.01% 5762
2018
Q2 		$45K Sell
14,744
-1,337
-8% -$4.95K ﹤0.01% 6198
2018
Q1 		$63K Sell
16,081
-22,428
-58% -$98.3K ﹤0.01% 5941
2017
Q4 		$173K Sell
38,509
-5,772
-13% -$27.3K ﹤0.01% 5473
2017
Q3 		$243K Buy
44,281
+8,874
+25% +$54.7K ﹤0.01% 5293
2017
Q2 		$269K Sell
35,407
-278,006
-89% -$1.2M ﹤0.01% 5185
2017
Q1 		$1.11M Sell
313,413
-37,731
-11% -$186K ﹤0.01% 4362
2016
Q4 		$2.01M Sell
351,144
-143,825
-29% -$960K ﹤0.01% 3769
2016
Q3 		$3.85M Buy
494,969
+8,423
+2% +$62.9K ﹤0.01% 3080
2016
Q2 		$3.03M Buy
486,546
+128,925
+36% +$1M ﹤0.01% 3259
2016
Q1 		$2.94M Sell
357,621
-5,402
-1% -$50.9K ﹤0.01% 3239
2015
Q4 		$6.29M Buy
363,023
+214,733
+145% +$3.19M ﹤0.01% 2717
2015
Q3 		$1.7M Buy
+148,290
New +$3.24M ﹤0.01% 3907

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bank of America's IBRX Position: Q1 2026 in Review

Bank of America increased its ImmunityBio (IBRX) stake by 2.7% in Q1 2026, buying an estimated $447K and bringing the position to 2,447,843 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

Bank of America first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $23.1M in Q2 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Bank of America held 2,447,843 shares of ImmunityBio worth $18.8M as of Q1 2026.
  • Bank of America bought 65,340 ImmunityBio shares in Q1 2026, an estimated $447K.
  • ImmunityBio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2444 holding.
  • Bank of America first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
  • Bank of America's ImmunityBio position peaked at $23.1M in Q2 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.